Ximelagatran: the first oral direct thrombin inhibitor

By Crowther Mark A   Weitz Jeffrey I  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 4, 2004-04 ,pp. : 403-413

Informa Healthcare

Access to resources Recommend Favorite

Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor

By Johansson L.C.   Frison L.   Logren U.   Fager G.   Gustafsson D.   Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 4, 2003-01 ,pp. : 381-392

Adis International

Access to resources Recommend Favorite

Population Pharmacokinetics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran, in Atrial Fibrillation Patients Receiving Long-Term Anticoagulation Therapy

By Bååthe Sofie  

Clinical Pharmacokinetics, Vol. 45, Iss. 8, 2006-01 ,pp. : 803-819

Adis International

Access to resources Recommend Favorite

Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions

By Bredberg E.   Andersson T.B.   Frison L.   Thuresson A.   Johansson S.   Eriksson-Lepkowska M.   Larsson M.   Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 8, 2003-01 ,pp. : 765-777

Adis International

Access to resources Recommend Favorite

Comparable Pharmacokinetics and Pharmacodynamics of Melagatran in Japanese and Caucasian Volunteers after Oral Administration of the Direct Thrombin Inhibitor Ximelagatran

By Wernevik Linda C.  

Clinical Pharmacokinetics, Vol. 45, Iss. 1, 2006-01 ,pp. : 85-94

Adis International

Access to resources Recommend Favorite